Literature DB >> 21671170

Variation of serum monocyte chemoattractant protein-1 in patients with diabetes and metabolic syndrome.

Huiqing Li1, Xiuling Deng1, Zhenqiong Li2, Changqing Luo2, Jianshe Liu2, Yumei Wang3.   

Abstract

This study investigated the variation of serum monocyte chemoattractant protein-1 (MCP-1) in patients with both diabetes mellitus (DM) and metabolic syndrome (MS). Based on the International Diabetes Federation (IDF) diagnostic criteria, 93 patients enrolled in this study were divided into four groups: normal control (NC), simple DM, simple MS, and DM plus MS (DM-MS) groups. The main measures included height, weight, waist circumference (WC), hip circumference, blood pressure, fasting blood glucose, insulin resistance index (HOMA-IR), serum triglyceride (TG), HDL-ch, LDL-ch, and MCP-1. The results showed that the serum levels of MCP-1 in the DM-MS group were significantly increased as compared with those in the DM and MS groups (P<0.05), and the increase in the MCP-1 level in the DM group was much higher than in the MS group (P<0.05). The DM-MS group had the highest HOMA-IR levels, followed by MS, DM and NC groups (P<0.05). Correlation tests showed that the association of MCP-1 with age, HDL-ch, or LDL-ch was insignificant, whereas that of MCP-1 with body mass index (BMI), waist hip rate (WHR), WC, systolic blood pressure (SBP), diastolic blood pressure (DBP), TG, and HOMA-IR was significantly positive. It was concluded that circulating MCP-1 was substantially increased in patients with both DM and MS as compared with that in the patients with DM or MS alone, and the central obese state may contribute to a more vicious proinflammatory condition and insulin resistance in patients with diabetes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21671170     DOI: 10.1007/s11596-011-0373-8

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  49 in total

Review 1.  Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

Authors:  K G M M Alberti; P Zimmet; J Shaw
Journal:  Diabet Med       Date:  2006-05       Impact factor: 4.359

Review 2.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

3.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

4.  IKK-beta links inflammation to obesity-induced insulin resistance.

Authors:  Melek C Arkan; Andrea L Hevener; Florian R Greten; Shin Maeda; Zhi-Wei Li; Jeffrey M Long; Anthony Wynshaw-Boris; Giuseppe Poli; Jerrold Olefsky; Michael Karin
Journal:  Nat Med       Date:  2005-01-30       Impact factor: 53.440

Review 5.  The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.

Authors:  Brent E Wisse
Journal:  J Am Soc Nephrol       Date:  2004-11       Impact factor: 10.121

6.  Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects.

Authors:  T Christiansen; B Richelsen; J M Bruun
Journal:  Int J Obes (Lond)       Date:  2005-01       Impact factor: 5.095

7.  Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters.

Authors:  C-S Kim; H-S Park; T Kawada; J-H Kim; D Lim; N E Hubbard; B-S Kwon; K L Erickson; R Yu
Journal:  Int J Obes (Lond)       Date:  2006-03-14       Impact factor: 5.095

8.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

9.  Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus.

Authors:  E Simeoni; M M Hoffmann; B R Winkelmann; J Ruiz; S Fleury; B O Boehm; W März; G Vassalli
Journal:  Diabetologia       Date:  2004-09-02       Impact factor: 10.122

Review 10.  Inflammatory pathways and insulin action.

Authors:  G S Hotamisligil
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12
View more
  2 in total

1.  Methylation status of CpG sites in the MCP-1 promoter is correlated to serum MCP-1 in Type 2 diabetes.

Authors:  Z H Liu; L L Chen; X L Deng; H J Song; Y F Liao; T S Zeng; J Zheng; H Q Li
Journal:  J Endocrinol Invest       Date:  2011-10-03       Impact factor: 4.256

Review 2.  Inflammation-Related Epigenetic Modification: The Bridge Between Immune and Metabolism in Type 2 Diabetes.

Authors:  Qiyou Ding; Zezheng Gao; Keyu Chen; Qiqi Zhang; Shiwan Hu; Linhua Zhao
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.